David Schlett joins Prime Therapeutics as Chief Financial Officer
Schlett is an experienced finance executive with more than 25 years of business, leadership experience
January 9, 2020
Schlett has deep roots in health care and the pharmacy industry. He held finance leadership positions at Medco and served as Express Scripts’ senior vice president of finance. Most recently he worked for Cambridge Advisory Group, and operated his own independent consultancy, providing financial, pharmacy and health care advisory services.
“Dave is a perfect fit for Prime,” said Prime’s President and CEO Ken Paulus. “As we searched for a new CFO, we were fortunate to have this well-respected, highly sought-after finance professional serve as an advisor to us this past year. Dave exhibited the depth and breadth of experience that Prime needs in this crucial position. We are delighted to have him join our team during this transformative time in health care.”
“I’m delighted to join Prime at this point in the company’s evolution,” said David Schlett, Prime’s new CFO. “The industry continues to evolve and Prime is uniquely positioned to create the PBM of the future, providing total drug management leading to better patient outcomes and lower plan cost.”
Schlett earned both a Master of Business Administration in Finance and a Bachelor of Arts in Business Administration and Accounting from Rutgers University in New Brunswick, NJ. He also is a certified public accountant (CPA).
October 19, 2021
Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation
EAGAN, Minn. and CAZENOVIA, NY – Prime Therapeutics (Prime), a leading pharmacy benefit…
October 18, 2021
Cancer patients, caregivers benefit with integrated clinic-to-pharmacy care through Prime Therapeutics’ IntegratedRx™ – Oncology
EAGAN, Minn. – Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving more…
October 14, 2021
In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates
EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…